For approximately a decade, biophysical methods have been used to validate positive hits selected from high-throughput screening (HTS) campaigns with the goal to verify binding interactions using label-free assays. By applying label-free readouts, screen artifacts created by compound interference and fluorescence are discovered, enabling further characterization of the hits for their target specificity and selectivity. The use of several biophysical methods to extract this type of highcontent information is required to prevent the promotion of false positives to the next level of hit validation and to select the best candidates for further chemical optimization. The typical technologies applied in this arena include dynamic light scattering, turbidometry, resonance waveguide, surface plasmon resonance, differential scanning fluorimetry, mass spectrometry, and others. Each technology can provide different types of information to enable the characterization of the binding interaction. Thus, these technologies can be incorporated in a hit-validation strategy not only according to the profile of chemical matter that is desired by the medicinal chemists, but also in a manner that is in agreement with the target protein's amenability to the screening format. Here, we present the results of screening strategies using biophysics with the objective to evaluate the approaches, discuss the advantages and challenges, and summarize the benefits in reference to lead discovery. In summary, the biophysics screens presented here demonstrated various hit rates from a list of ~2000 preselected, IC 50 -validated hits from HTS (an IC50 is the inhibitor concentration at which 50% inhibition of activity is observed). There are several lessons learned from these biophysical screens, which will be discussed in this article.
Introduction
With the initiation of high-throughput screening (HTS) and the ease of its implementation and application in drug discovery, the necessity to classify and characterize low-molecularweight hits was created not only to validate the results of HTS but also to cull the hit number to a digestible sum for candidate follow-up. This has led to the creation of orthogonal screening and counter-screening procedures to prevent false positives from being promoted to the next step of hit validation. 1 Methods in medium-to high-throughput (HT) biophysics were then developed to validate, confirm, and in addition profile these lead candidates for their specificity and selectivity toward the target. The main purpose of medium-throughput to HT biophysics is to provide such hits an expedient, focused, and decisive entryway into lead optimization. Supplemental Table S1 and Supplemental Figure S1 display a list of biophysical techniques and a generic hit-finding strategy delineating the different types of approaches used in hit validation with brief descriptions of the information gleaned from their application in the hit-finding process. Fragment-based screening (FBS) is another approach to lead finding that also uses biophysics; however, this subject merits its own discussion separately from low-molecular-weight compounds, and thus it will not be discussed in this article. confirm binding interactions of the compound or inhibitor to the target protein of interest, in a label-free manner. Each type of technology has its own strengths in the approach it uses to determine the validity of a binding interaction or its throughput, or in the type of detailed information one can extract about the binding affinity. Technologies that detect the presence of a binding interaction in the most high-throughput manner are affinity selection mass spectrometry (AS-MS), resonant waveguide (RWG), and surface plasmon resonance (SPR), in which evidence of a binding event is detected by the ability of the technologies to monitor changes in populations of bound and unbound inhibitor to target or changes in mass on inhibitor binding to target immobilized on a sensor surface (RWG and SPR). 2, 3, 4, 5 Other technologies such as differential scanning fluorimetry (DSF) and microscale thermophoresis (MST) offer a simple in-solution method of relatively low protein consumption to detect binding at saturation. At the core of these technologies is the ability to quickly detect changes in thermal stabilization of the target on inhibitor binding (DSF) or monitor changes in protein surface solvation or charge on inhibitor binding in relation to their migration in a temperature gradient, as with MST. 6, 7 Detailed affinity data, which reveal the mode of binding, the binding energies of an interaction, and its stoichiometry, can be obtained by using such approaches as nuclear magnetic resonance (NMR) or isothermal titration calorimetry (ITC). 8, 9 These technologies have improved greatly in recent years, with respect to their protein consumption and throughput capabilities. Alternatives to ITC and SPR can be found in differential scanning calorimetry (DSC) and biolayer interferometry (BLI), respectively, which offer alternative modes of detection by monitoring the change in thermal unfolding in the presence of compounds (DSC) or the differences in interference patterns when a compound binds to the target at the solvent interface. 10, 11 
Generic Biophysics Screen Flow Chart
Supplemental Figure S1 displays an example of a biophysics flow chart, in which the technologies are placed in the most common order of usage, according to their throughput, robustness, and sensitivity. As one can see, the hitvalidation process is much like an hourglass. To find chemical matter that is specific and selective, the process usually starts with a wide base of possible candidates that originate from a large collection or from a focused selection of candidates chosen according to their prevalence in literature, their common chemical characteristics, or even the knowledge obtained from previous screens performed on similar target members. Once these hits have been screened, highthroughput biophysics aids in confirming and validating these candidates, prioritizing them for further characterization and chemical optimization. Several rounds of this type of characterization on various analogs of the validated hit can help in guiding compound optimization and advance the candidate to lead status.
As Supplemental Table S1 and Supplemental Figure S1 illustrate, there are many technologies that can be used to support hit validation at different stages; however, whether it makes sense to use all the methods in hit validation is another question. Very simply, there are several questions that can be asked to decide which strategy to use. For example, is the target not very well characterized, and is it a part of a new family of proteins that have several disease indications? Has the target already been screened before, and are there well-characterized compound sets available? Is the target part of a multiprotein complex? Is the desired mode of inhibition within a protein-protein interface or within a binding pocket? Are allosteric inhibitors of the interaction desired? The next practical considerations, which influence which strategy to choose, are the resources available, if there is plenty of target protein on hand, and if there are restrictions in project timelines.
To illustrate and answer these questions, several screening approaches in biophysics will be discussed in this article, using a format in which the screen aim will be presented, and focusing on the hit-finding goal of the project and the technologies used to validate and deliver the desired set of compounds. Because the main purpose of this article is to discuss the biophysics validation approach with respect to the biochemistry of the target, details about the target itself or its mode of action in disease pathology, in some cases, will not be revealed.
Screen Approach: Validation of HTS Hits from a New Epigenetic Target Family Using Biophysics
A target from a new family of proteins thought to be involved in a particular disease pathology requires full "biophysical" attention to understand and design a screen that not only respects the biochemical profile of the target but also fulfills the aim of the screening campaign. While developing a screening assay, it is important that any potential caveats hidden within a chosen screen approach are revealed, thereby ensuring that the screening format itself does not falsify the hit rate or create nonlogical trends in the scaffold profiles of the hits, for example the misalignment of SPR affinity data with the time-resolved fluorescence resonance energy transfer (TR-FRET) results. Because the purpose of this article is to demonstrate how to construct a logical biophysics hitvalidation scheme, an in-depth examination and discussion of dissecting or troubleshooting the misalignment of data with other approaches such as TR-FRET will not be presented here.
Once an understanding of how the target behaves in certain screening formats is cataloged, one can then approach the next class of similar targets in a streamlined manner, that is, leveraging certain technologies early and quickly to get the most relevant data and promote these hits to the next level of characterization. In the supporting examples, we will discuss the aim of a screening campaign for target A, a new target family, its related family member, and target B. The screening strategy for target A and target B, and how their results can be used to shape the next screening campaign for other epigenetic targets, will be presented. A summary of their outcomes quantified by the percentage confirmation of the HTS hits, the number of hit scaffolds promoted to the next level of characterization, and the number of scaffolds deemed worthy of further medicinalchemistry efforts will be discussed.
Screen Aim for Target A
Globally, epigenetics and its role in disease pathology command tremendous interest in academia and in industry. The permeation of target A, an epigenetic modulator, was one of several chosen as an entryway into this particular field of epigenetic drug discovery. The screen aim was to validate reversible competitive inhibitors of target A, its domains, and target B (selected from an HTS screen performed using a TR-FRET assay). The desired inhibitors were predicted to have one of two profiles: (1) selectively inhibit target A via one of its domains, or (2) pan-inhibit several targets within the same target family, such as target B. Currently, target A is not well characterized biochemically; it is not known which domain of target A is pathologically relevant, whether these domains interact cooperatively, or if its binding pocket could be regulated allosterically. Thus, the HTS hit-finding strategy was designed to screen broadly to capture all possible molecules. It was known at the time that this particular target was not part of a multiprotein complex, and thus certain biophysical approaches were not used, such as AS-MS. Another interesting challenge about target A was discovered inadvertently using DSF, which revealed that target A was thermally stabilized by DMSO, a common diluent used for compound solubilization. DSF, at this moment in time in the project, was being used to screen a set of constructs and buffer conditions to optimize production capabilities and investigate construct robustness for certain biophysical assays. Traditionally, DMSO is routinely investigated to observe how well the target can handle this solvent, which is then used as a guide to know which concentration of compound or DMSO can be used in the biophysics assay. After this initial finding, DMSO binding was also confirmed via NMR to quantitate the K D of DMSO and in X-ray crystallography to understand where this solvent molecule was binding (data not shown); and, indeed, the molecule was found in the active site. Due to these unique factors, the biophysical characterization of target A received the utmost priority to guide screening assay development at all levels of the hit-finding flow chart and to streamline the subsequent screening campaigns for other family members.
Screen Aim for Set7/9
To illustrate how a biophysics validation strategy can serve as the basis to trim the hit-finding efforts for other targets, Set 7/9 (otherwise known as SetD7) will be used to exemplify this approach. Set7/9 is an epigenetic target of strategic importance to the modulation of DNA transcription. In this hit-finding approach, reversible competitive inhibitors were preferred that block the ability of Set7/9 to bind histone peptide tails. With the knowledge obtained from the epigenetic target-screening strategies, DSF was used as the primary screening approach for Set7/9 to quickly drill down to the most interesting scaffolds to expedite their promotion to chemical optimization.
Materials, Methods, and Target Background Description
These sections are located in the supplemental information.
Results

Pilot Screen for Target A
A pilot screen was performed using 18 selected compounds of various affinity ranges to determine the amenability of target A to various biophysical-screening formats. Supplemental  Table S2 and Figure 1 show the pilot screen flow chart and its results. The origins of these "pre-HTS" compounds were from various sources: a focused TR-FRET screen, literature, and in silico docking activities. Because it was not known at the time of the HTS screen campaign whether the domains of target A interacted cooperatively to cause a conformational change and augment its activity, care was taken to perform a biophysics pilot screen of target A in solution and also in an immobilized format to ensure that various binding interactions could be captured. As one can see in Figure 1 , the greatest confirmation rates to TR-FRET were observed between the RWG and DSF technologies, whereas SPR gave a modest confirmation rate. Supplemental Table S2 lists the actual K D 's and binding interactions detected using each technology in comparison to TR-FRET. Both RWG and DSF showed significant agreement with the TR-FRET data. Figure 2 displays SPR data obtained from compounds A, F, and G. As one can see, SPR is a relatively challenging but informative approach to use as a screen in biophysics hit validation: compounds may bind in a specific manner in other biophysical assays but fail in SPR due to suboptimal binding characteristics. The cause of this discrepancy may be the lack of compound solubility at higher concentrations or the compound's tendency to stick to the target and not dissociate, which can then cause nonclassical SPR binding curves. According to the SPR data of compound A, the immobilized target surface was quite active and was calculated to be 94.2%. This calculation is based on the molecular weight of the target and compound A, and in addition, the amount of target immobilized. A comparison of the expected SPR response to the actual SPR response of compound A confirmed its 1:1 binding stoichiometry and specificity. Based on the SPR data of compound F and its molecular weight, it was calculated that multiple molecules of compound F were, in fact, binding to the target at a ratio of 24:1. The superstoichiometric behavior of compound F was not due to a compromised target surface but, rather, the compound itself and its "stickiness" to the target. This unwanted behavior can compromise the target, rendering it inactive for the next compound interaction. Compound G looked promising due to its RWG and DSF results; however, when it was analyzed via SPR, saturation of the target surface with compound G was not achieved. Therefore, an affinity at equilibrium for compound G could not be calculated. Compound G was rerun again to verify that its behavior was not due to the previous compound's suboptimal or sticky interaction with the target. As one can imagine, rerunning large portions of a screen due to sticky compounds can be time consuming and expensive. Thus, a screening solution will be discussed in the following section.
At lower affinity ranges, RWG could detect binding, whereas DSF appears to have only a 50% confirmation rate in comparison to RWG. This did not reflect the incapability of the DSF technology to detect weak hits, but actually indicated that if weaker hits were desired by the project team to find new chemical space, a higher concentration of compound would be necessary so that target saturation is achieved and a DSF signal is observed (data not shown).
Biophysics Screen for Target A
As one can see in Supplemental Figure S3 , RWG and DSF were positioned upstream of SPR to ensure the specificity of the TR-FRET hits prior to SPR in the actual biophysics validation approach for target A. To note, their placement reflected the desire to find hits in both target formats: surface bound and also in solution. In addition, these formats ensured that if the domains were cooperative, the screen approach would not select out these types of compounds inadvertently. Screening at a low-enough target immobilization level in SPR, to allow freedom of target movement without loss of signal, certified that these target structural changes could still occur. Thus, these preferential, in-solution DSF hits would not be inadvertently deselected by the SPR screening process.
As described in the supplemental information, turbidometry data were then merged with the binding signal data to flag any potential problems in RWG or DSF prior to SPR. SPR itself is crucially liable to compound artifacts, because it is a method that serially injects each compound over the same target surface. Thus, if there is, by chance, a compound that binds in a superstoichiometric manner or aggregates and does not dissociate from the target surface, the ability for the next compound to bind and be detected may be compromised. To circumvent this, an SPR clean screen was performed on target A and its family members prior to the actual SPR binding screen. A clean screen is, as its name indicates, a screen in which one deselects compounds for nondesirable behavior in the SPR screen format. 13 Very simply, a target is immobilized on the SPR sensor surface, and the compounds are injected over the surface. The compounds are then annotated for their ability to bind irreversibly to the target or to the reference surface alone.
Supplemental Figure S4 displays the HTS TR-FRET confirmation rates at each step of the biophysics screen flow chart with respect to each technology. As one can see, the overall results show in Supplemental Figure S4 complement quite nicely those of Figure 1 , in that the biophysics validation confirmation rates reflected those that were predicted in the pilot screen approach. With reference to the DSF technology, those TR-FRET hits that were confirmed at an early stage in the biophysics flow chart by DSF retained their promising confirmation profile and were not screened out due to sensor matrix effects or an inability to be detected by SPR. Please refer to the supplemental information for details on how the DSF data were evaluated and for a discussion of hit evaluation.
RWG confirmation results, in contrast, were reasonably challenged by SPR. This is evident by the fact that about 20% of these types of hits did not survive the SPR clean screen process. This failure rate was not due to the compounds sticking to the SPR sensor surface, but in fact it was caused by improper dissociation of the compound from the target. Figure 3 depicts an example of this type of result. The RWG assay read data of compound C17 displayed a healthy signal that was in agreement with its molecular weight and the amount of target immobilized. However, in SPR, C17 demonstrated a lack of dissociation from target A. This nonspecific binding issue was not revealed by the The confirmation rates (in %) between the different technologies used in the pilot screen of Target A. For this study, 18 compounds that were previously validated via time-resolved fluorescence resonance energy transfer were used to investigate the capability of Target A to be screened using these different biophysical approaches for high-throughput screening hit validation.
RWG screen format, in which binding data can be rapidly detected and quantified. Due to the lack of a buffer injection and flow system in the RWG instrumentation, additional information about compound dissociation was not obtained. Due to its flow system, SPR can dissect the binding signal by looking at the stickiness of the compound or its dissociation rate as it comes off the target, without placing extra manual steps in the screen assay.
The results displayed in Supplemental Figure S6 show that several unique hits were found for each target (please refer to supplemental information). To further verify these hits from the SPR binding assay, a SPR affinity screen was performed in which the binding interaction, specificity, and affinity were assessed using a compound concentration series. The selection of these hits came mainly from the DSF and RWG screen and not the cell-based assay screen. The selection reasoning was twofold: first, a compound can fail in a cell-based assay for various causes, for example due to solubility. In most cases, the solubility of the compound can be improved on with chemical optimization; thus, failure at the cell-based assay was not disconcerting. Second, DSF is an in-solution direct-binding assay that theoretically could reap hits with various binding modes of action, such as those with allosteric profiles or those that cause a conformational change. Therefore, these types of hits could be characterized further using SPR. In summary, DSF was used to highlight those scaffolds that should be investigated further via SPR. RWG was used to confirm or rescue the DSF screen hits.
The SPR validation characterized the hits further and prioritized their placement for studies in X-ray and NMR, according to their binding affinity. 14 To aid in the prioritization, the SPR affinity hits were placed in categories according to such qualities that answered the following questions: Supplemental  Table S2 , displaying compounds A, F, and G from the pilot screen of Target A. These sensograms demonstrated some of the usual types of interactions one can detect via SPR: 1:1 binding (compound A), superstoichiometric binding (compound F), and binding without target saturation (compound G). Figure 3 . The misalignment of binding interaction data between resonant waveguide (RWG) and surface plasmon resonance (SPR) using compound C17 as an example. In RWG, C17 displayed a healthy RWG signal (a 38.9 picometer shift); however, in SPR, this compound exhibited the tendency to bind irreversibly to Target A. did the compound behave specifically with the target, or did it bind and not dissociate in a timely manner? Were the curvature and time scale of compound association and dissociation in agreement with the affinity estimated from other approaches? Did the response reach equilibrium or saturation? If saturation was not reached, did a higher concentration series of compound help or cause problems in the SPR readout? Did the compound exhibit a dose response that was in accordance with its molecular weight? Could an affinity at equilibrium be assigned or just estimated? How did the SPR affinity measurement compare to the IC50's or K D 's from other approaches? Did the compound show target selectivity or selectivity for a particular domain of target A?
From the 60 compounds chosen for the SPR affinity screen, approximately 40% passed; that is, for these compounds, an affinity at equilibrium could be assigned using SPR that was in accordance with previous validation data. Of the 40% hits that passed, their affinity ranges were from 0.005 to 25 uM (micromolar), with the greatest percentage falling in the range from 1 to 10 uM. The other hits displayed a specific dose response and curvature that were in accordance to their previously described affinity profile; however, these hits did not reach equilibrium or saturation, and therefore a K D could only be estimated. In summary, the SPR affinity screen data were reported to the medicinalchemistry team in comparison to all other affinity data with the following SPR-specific descriptions: HIT (SPR K D = XX uM), INCONCLUSIVE (specific dose response observed without saturation or nonspecific binding to the sensor), and NO HIT (with one of these descriptors: no binding to target or nonspecific binding to target). This type of information helped track where the hits failed to reach the next level of interrogation. Categorizing the data in this manner also aided in refocusing project resources toward investigating the inconclusive hits via another approach, such as NMR or by placing the inconclusive hits on hold for further work-up in the future, if the "best-in-class" compounds failed at another stage of analysis.
Biophysics Screen for Set7/9
Using this knowledge, DSF was used as the main approach for gleaning chemical starting points for the next HTS screen. Figure 4 displays one such compound found in the Set7/9 DSF screen, displaying its thermal stabilization profile. 18 The first detail to notice in this plot is that the starting intensity (blue curve) was not elevated, indicating that the compound did not cause protein aggregation. As one can see from the clear, sharp hyperbolic shape of the melting curve (orange dashed line) and the magnitude of change in fluorescence intensity, a large thermal stabilization was obtained for this scaffold, equaling 3.2 °C. At higher temperatures, as shown on the right-hand side of the curve, a decrease in SYPRO Orange fluorescence intensity was observed. As the protein succumbs to aggregation, the SYPRO Orange disengages from the hydrophobic core of the protein and naturally loses its fluorescence. It was discovered that DMSO alone also causes a shift in thermal stabilization for Set7/9; therefore, all screening data were adjusted accordingly. The DMSO thermal stabilization contribution was approximately the same for both of these types of epigenetic targets (data not shown). Figure 5 shows the corresponding SPR affinity data for this compound. The curvature of the sensograms demonstrated that the compound's interaction with Set7/9 was specific: the compound associated and dissociated in a timely manner from the target, reaching equilibrium after approximately 25 s. According to the molecular mass calculations, the predicted response signal should be 27.8 RUs, which is in close agreement to what was obtained at saturation, 22-26 RUs, indicating that the interaction was not superstoichiometric. The binding efficiency of the immobilized target was calculated to be 80-94%, indicating the surface was active, with the target's binding pocket readily accessible for compound interaction. The curvature of the association and dissociation phases predicted that the compound would possess a midrange micromolar affinity. This was in alignment with its calculated value of 8.8 uM.
Overall, approximately 25% of the scaffolds interrogated by the Set 7/9 HTS were confirmed DSF. Of those DSF hits, three major scaffolds were represented in 40% of the hits; thus, the most chemically attractive hits were chosen for further chemical optimization. For more details on how the DSF and SPR screens were conducted, please refer to the supplemental information.
Discussion
As shown in the various biophysics screening approaches presented, there are a number of different methods that can be implemented to validate hits garnered from HTS or any other large screening campaign. In addition, there are several ways one can place these methods to strategically obtain candidates that fulfill the necessary biochemical requirements for further lead-optimization efforts. With this collective knowledge gained from screening using biophysics, there are several points that are worthy to note and that should be considered when designing a biophysics flow chart for hit validation.
For target A, little was known about the manner in which it would interact with its binding partner; thus, a broader screening approach was used to ensure that hits could be obtained in either screening format: via target immobilization or in solution. Even between the immobilization approaches for RWG and SPR, there were differences in the content and in the type of affinity data obtained. The type of binding data from RWG was limited by the lack of an instrument flow system, without which the dissociation behavior of the inhibitor could not be monitored. Although RWG does not possess this functionality, it is highly valued for its ability to quickly determine binding interactions and assign an apparent K D . To understand the strengths and challenges for RWG and SPR further and where they diverge in their results to TR-FRET, an analysis of the K D results between RWG and SPR versus TR-FRET IC 50 's was done for target A. Overall, it was observed that both RWG and SPR gave the same trend in K D affinities in comparison to TR-FRET IC 50 's (data not shown). Because both technologies have the capability to confirm hits from TR-FRET, their placement in the screen approach was structured in such a way to emphasize their strengths and abilities to confirm hits in a swift manner. Both RWG and DSF technologies are relatively fast in their screening capabilities: RWG can scan a 384-well plate in 2 min (newer RWGgeneration instruments are currently available that can scan 384 wells in 12 s), whereas DSF takes approximately 7 min for 384 wells; thus, they are very useful in screening expediently and culling the hits for SPR. Therefore, RWG and DSF were placed upstream of SPR in the biophysics hit-validation scheme.
Not only is throughput important to a hit validation strategy, but also the screen setup is, that is, how each compound is introduced to the target to monitor their binding interactions. Both RWG and DSF are plate-based assays in which each compound is analyzed in a separate well, preventing secondary compound effects from interfering with the ability of the next compound to interact with the target protein. This is unlike an SPR setup, which involves the serial injection of compounds over the same target surface. SPR can lend high-content data to a screen approach with its ability to assign affinity and kinetic information to the interaction between the compound and target, albeit at the cost of processing time. One of the strengths of SPR is its low protein usage and its ability to screen in a multiplex manner, that is, several targets at once. Thus, SPR was better placed downstream to RWG and DSF, where it was used to confirm the hits and profile them for their ability to interact with various targets, for example target A, its individual domains, and target B, within the same screen without requiring tremendous protein-production resources.
In every hit-validation approach, it is equally important to look at the false-negative and false-positive hits and perform an analysis as to where and how these hits were created in the biophysics confirmation process. For target A, two compound characteristics were quantified to understand the origins of false-negative and false-positive hits. For these purposes, compound aggregation and characterization of the binding interaction were tracked. Using turbidometry, it was revealed that most compounds did not aggregate in the screen-assay buffer; hence, compound aggregation was not the main source of false positives in this validation strategy. In comparing the DSF results to RWG, it was discovered that RWG rescued 25% of DSF nonhits. Hence, DSF can generate false negatives. Thus, it is recommended to use DSF as an opportunistic approach to quickly find chemical starting points for optimization. By using the SPR clean screen, the compounds that passed either RWG or DSF were profiled for their binding stoichiometry, their ability to dissociate from the target, and their "stickiness" to the SPR sensor surface. Of those compounds that passed RWG and DSF but failed in the SPR clean screen, the principle reason for failure was their improper dissociation from the target, a parameter that is unquantifiable using RWG or DSF. Therefore, the follow-up of RWG or DSF using an SPR clean screen quickly confirmed the truly positive hits from these technologies.
In light of these biophysics validation results, it was theorized that a more streamlined approach in biophysics for another epigenetic target could be taken without a loss of hit material. In reference to target A, the DSF itself contributed robustly to the lead-finding efforts by promoting approximately 40% of the original HTS hits to the final biophysics hit list for medicinal-chemistry consideration. In the case of Set7/9, this streamlined approach was also shown to be robust in its output, generating scaffolds worthy of chemical optimization.
In summary, there are several biophysical approaches that can be used to flush out the real hits from an HTS campaign and prioritize compounds for further chemical optimization. As with every screen campaign and the validation of hits, one should consider what biophysical data are truly needed to promote a candidate to the next level of resourcedemanding work. For example, if the project team wishes to have kinetic information on the hits at an early stage in drug discovery, then an SPR clean screen and SPR binding assay are essential to processing and profiling a large number of hits to prioritize their placement in an SPR kinetics assay. The amount of time needed for just the SPR segment of the validation process should be challenged with a question such as: what sort of data does the project team really need to choose a compound for chemical optimization? This question can be addressed by designing a biophysics flowchart that is tactful in its approach, placing certain technologies at the forefront and others at the characterization and optimization stages of drug discovery. It is during the validation phase of lead finding, after which a few high-quality scaffolds have been chosen, that more resources could be dedicated to profiling compounds by their on and off rates or their binding energies to fine-tune their efficacy.
